304 related articles for article (PubMed ID: 28852271)
21. Emerging Biomarkers Beyond Leukotrienes for the Management of Nonsteroidal Anti-inflammatory Drug (NSAID)-Exacerbated Respiratory Disease.
Rhyou HI; Nam YH; Park HS
Allergy Asthma Immunol Res; 2022 Mar; 14(2):153-167. PubMed ID: 35255534
[TBL] [Abstract][Full Text] [Related]
22. Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity.
Mastalerz L; Celejewska-Wójcik N; Wójcik K; Gielicz A; Januszek R; Cholewa A; Stręk P; Sanak M
Allergy; 2014 Nov; 69(11):1550-9. PubMed ID: 25123806
[TBL] [Abstract][Full Text] [Related]
23. Immunologic effects of aspirin desensitization and high-dose aspirin therapy in aspirin-exacerbated respiratory disease.
Cahill KN
J Allergy Clin Immunol; 2021 Aug; 148(2):344-347. PubMed ID: 34144108
[No Abstract] [Full Text] [Related]
24. Sex, Ethnicity, Body Mass Index, and Environmental Exposures Associated With NSAID-Exacerbated Respiratory Disease Symptom Sequence.
Dages KN; Sofola-James O; Sehanobish E; Regula P; Chen CC; Chiarella SE; Divekar RD; Cohen HW; Jerschow E
J Allergy Clin Immunol Pract; 2023 Dec; 11(12):3662-3669.e2. PubMed ID: 37541619
[TBL] [Abstract][Full Text] [Related]
25. Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria.
Porcaro F; Di Marco A; Cutrera R
Pediatr Pulmonol; 2017 May; 52(5):E26-E28. PubMed ID: 27685608
[TBL] [Abstract][Full Text] [Related]
26. Clinical Characteristics of Aspirin-Exacerbated Respiratory Disease.
Stevenson DD; White AA
Immunol Allergy Clin North Am; 2016 Nov; 36(4):643-655. PubMed ID: 27712760
[TBL] [Abstract][Full Text] [Related]
27. Eosinophilic Asthma.
Nelson RK; Bush A; Stokes J; Nair P; Akuthota P
J Allergy Clin Immunol Pract; 2020 Feb; 8(2):465-473. PubMed ID: 31786254
[TBL] [Abstract][Full Text] [Related]
28. Dipeptidyl-peptidase 10 as a genetic biomarker for the aspirin-exacerbated respiratory disease phenotype.
Kim SH; Choi H; Yoon MG; Ye YM; Park HS
Ann Allergy Asthma Immunol; 2015 Mar; 114(3):208-13. PubMed ID: 25592153
[TBL] [Abstract][Full Text] [Related]
29. [Aspirin-exacerbated respiratory disease].
Randerath WJ
Dtsch Med Wochenschr; 2013 Mar; 138(11):541-7. PubMed ID: 23463477
[TBL] [Abstract][Full Text] [Related]
30. Tolerability to etoricoxib in patients with aspirin-exacerbated respiratory disease.
Koschel D; Weber CN; Höffken G
J Investig Allergol Clin Immunol; 2013; 23(4):275-80. PubMed ID: 23964558
[TBL] [Abstract][Full Text] [Related]
31. Safety of parecoxib in asthmatic patients with aspirin-exacerbated respiratory disease.
Valero A; Sánchez-López J; Bartra J; Serrano C; Muñoz-Cano R; Roca J; Picado C
Int Arch Allergy Immunol; 2011; 156(2):221-3. PubMed ID: 21597303
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper.
Kowalski ML; Agache I; Bavbek S; Bakirtas A; Blanca M; Bochenek G; Bonini M; Heffler E; Klimek L; Laidlaw TM; Mullol J; Niżankowska-Mogilnicka E; Park HS; Sanak M; Sanchez-Borges M; Sanchez-Garcia S; Scadding G; Taniguchi M; Torres MJ; White AA; Wardzyńska A
Allergy; 2019 Jan; 74(1):28-39. PubMed ID: 30216468
[TBL] [Abstract][Full Text] [Related]
33. NSAID-Exacerbated Respiratory Disease (NERD): From Pathogenesis to Improved Care.
Woo SD; Luu QQ; Park HS
Front Pharmacol; 2020; 11():1147. PubMed ID: 32848759
[TBL] [Abstract][Full Text] [Related]
34. Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease.
Mitsui C; Kajiwara K; Hayashi H; Ito J; Mita H; Ono E; Higashi N; Fukutomi Y; Sekiya K; Tsuburai T; Akiyama K; Yamamoto K; Taniguchi M
J Allergy Clin Immunol; 2016 Feb; 137(2):400-11. PubMed ID: 26194538
[TBL] [Abstract][Full Text] [Related]
35. Aspirin Exacerbated Respiratory Disease.
Fruth K; Gosepath J
Adv Otorhinolaryngol; 2016; 79():21-8. PubMed ID: 27466843
[TBL] [Abstract][Full Text] [Related]
36. Genetic variants in arachidonic acid pathway genes associated with NSAID-exacerbated respiratory disease.
Ayuso P; Plaza-Serón Mdel C; Blanca-López N; Doña I; Campo P; Canto G; Laguna JJ; Bartra J; Soriano-Gomis V; Blanca M; Cornejo-García JA; Perkins JR
Pharmacogenomics; 2015 Jul; 16(8):825-39. PubMed ID: 26067486
[TBL] [Abstract][Full Text] [Related]
37. Associations between TMEM196 polymorphisms and NSAID-exacerbated respiratory disease in asthma.
Lee JU; Chang HS; Baek DG; Shin HD; Park CS; Park JS
Pharmacogenet Genomics; 2019 Jun; 29(4):69-75. PubMed ID: 30694883
[TBL] [Abstract][Full Text] [Related]
38. Aspirin-exacerbated respiratory disease: burden of disease.
Chang JE; White A; Simon RA; Stevenson DD
Allergy Asthma Proc; 2012; 33(2):117-21. PubMed ID: 22525387
[TBL] [Abstract][Full Text] [Related]
39. Clinical Characteristics, Urinary Leukotriene E4 Levels, and Aspirin Desensitization Results in Patients With NSAID-Induced Blended Reactions.
Klaewsongkram J; Buranapraditkun S; Mongkolpathumrat P; Palapinyo S; Chantaphakul H
Allergy Asthma Immunol Res; 2021 Mar; 13(2):229-244. PubMed ID: 33474858
[TBL] [Abstract][Full Text] [Related]
40. Aspirin-Exacerbated Respiratory Disease: The Hunt for the "Rosetta Stone" of Respiratory Inflammation.
White AA
Immunol Allergy Clin North Am; 2016 Nov; 36(4):xv-xvi. PubMed ID: 27712771
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
